What is the total value of the acquisition?

The total potential value includes an upfront cash payment of $115.00 per share plus a contingent payment of $5.00 per share via a CVR, making the maximum potential per-share consideration $120.00. The total acquisition value will depend on the number of Arcellx shares outstanding and the ultimate payout of the CVR.

What is anito-cel and why is it important for Gilead?

Anito-cel is Arcellx's BCMA-targeting ddCAR product candidate for patients with relapsed or refractory multiple myeloma. Its FDA acceptance for BLA review signifies its potential as a valuable asset, and acquiring it enhances Gilead's oncology pipeline and therapeutic offerings in a critical disease area.

What are the key conditions for the tender offer and merger to be completed?

Key conditions include the tender of a majority of Arcellx's outstanding shares, the expiration or termination of the Hart-Scott-Rodino waiting period and other antitrust approvals, the absence of any legal prohibition of the transaction, and the accuracy of representations and warranties made by Arcellx, among other customary closing conditions.

GILD 8-K: Material Agreements & Regulation FD

Q: What is the significance of the CVR for Arcellx shareholders?

The CVR offers Arcellx shareholders the potential for an additional $5.00 per share if Arcellx's anito-cel product achieves $6 billion in cumulative worldwide sales by December 31, 2029. This aligns shareholder interests with the future commercial success of anito-cel.

Summary

Gilead Sciences, Inc. has entered into a definitive agreement to acquire Arcellx, Inc. for a combination of cash and a contingent value right (CVR). The offer includes an upfront cash payment of $115.00 per share, plus a CVR entitling holders to an additional $5.00 per share if Arcellx's anito-cel product achieves $6 billion in cumulative worldwide sales by December 31, 2029. This acquisition represents a significant strategic move for Gilead, aiming to bolster its oncology pipeline with Arcellx's promising BCMA-targeting ddCAR product candidate, anito-cel, which has also received FDA acceptance for its Biologics License Application. The transaction is structured as a tender offer, where Gilead's subsidiary will commence an offer to acquire all outstanding shares of Arcellx. The deal is subject to customary closing conditions, including a majority tender of Arcellx shares and antitrust approvals. Management and significant shareholders of Arcellx have entered into support agreements to tender their shares, representing approximately 10.3% of outstanding shares. This acquisition is expected to enhance Gilead's position in the competitive oncology market, particularly in the treatment of relapsed or refractory multiple myeloma.

Key Highlights

1Gilead Sciences to acquire Arcellx, Inc. for a combination of cash and a contingent value right (CVR).
2The offer includes an upfront cash payment of $115.00 per share plus a potential $5.00 per share CVR.
3The CVR payment is contingent on Arcellx's anito-cel product achieving $6 billion in cumulative worldwide sales by December 31, 2029.
4Arcellx's anito-cel (a BCMA-targeting ddCAR product candidate) has received FDA acceptance for its Biologics License Application (BLA) for relapsed or refractory multiple myeloma.
5The transaction will commence with a tender offer by a Gilead subsidiary for all outstanding Arcellx shares.
6Approximately 10.3% of Arcellx's outstanding shares are subject to tender and support agreements from key management and investors.
7The deal is subject to customary closing conditions, including regulatory approvals and a majority tender of shares.

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Feb 23, 2026)

Summary

Key Highlights

Frequently Asked Questions